Programmed death ligand 1 expression has been reported in 20% to 30% of patients with UC, often associated with higher disease stages.35 Moreover, PD-L1 positivity, especially at higher levels of expression, is negatively prognostic for OS and disease-free survival in UC, particularly bladder cancer.36,37 In other reports, high PD-L1 expression on immune cells has been linked to a more favorable prognosis.37 Our systematic review and meta-analysis results for ORR, OS, and PFS indicate a positive prognostic role of PD-L1 when ICIs are administered. The gene discussed is CD274; the disease is urinary bladder carcinoma.